<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02080871</url>
  </required_header>
  <id_info>
    <org_study_id>BES 10-07</org_study_id>
    <nct_id>NCT02080871</nct_id>
  </id_info>
  <brief_title>A Study of the Gore VIABAHN BX for Treatment of Occlusive Disease in the Iliac Arteries.</brief_title>
  <acronym>VBXFLEX</acronym>
  <official_title>Evaluation of the Gore(R) Viabahn(R) Balloon Expandable Endoprosthesis (VIABAHN BX) for the Treatment of Occlusive Disease in the Common and External Iliac Arteries.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>W.L.Gore &amp; Associates</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>W.L.Gore &amp; Associates</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the Gore(R) VIABAHN BX for the treatment of arterial occlusive disease in the
      common and/or external iliac arteries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a prospective, multicenter, non-randomized single-arm clinical study to
      evaluate the safety and efficacy of the VIABAHN BX for the treatment of arterial occlusive
      disease in patients with de novo or restenotic lesions in the common and/or external iliac
      arteries.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2014</start_date>
  <completion_date type="Actual">October 2018</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of Major Adverse Events (MAEs)</measure>
    <time_frame>9 months</time_frame>
    <description>Percentage of study subjects experiencing a major adverse event (MAE) defined as: device or procedure-related death within 30 days, myocardial infarction (MI) within 30 days, target lesion revascularization (TLR) within 9 months or major amputation of the target limb within 9 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute Procedural Success</measure>
    <time_frame>Discharge</time_frame>
    <description>Number of subjects who experienced Acute Procedural Success defined as less than or equal to 30% residual stenosis prior to procedure completion and no device- or procedure-related SAEs before discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-Day Clinical Success</measure>
    <time_frame>30 Days</time_frame>
    <description>Number of subjects who experienced 30-Day Clinical Success defined as an improvement of at least one Rutherford Category at the 30-day visit as compared to pre-procedure and no device- or procedure-related SAEs within 30 days of the index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Primary Patency</measure>
    <time_frame>30 Days</time_frame>
    <description>Kaplan-Meier estimate of primary patency at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Primary Patency</measure>
    <time_frame>9 Months</time_frame>
    <description>Kaplan-Meier estimate of primary patency at 9 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Primary Assisted Patency</measure>
    <time_frame>30 Days</time_frame>
    <description>Kaplan-Meier estimate of primary assisted patency at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Primary Assisted Patency</measure>
    <time_frame>9 Months</time_frame>
    <description>Kaplan-Meier estimate of primary assisted patency at 9 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Secondary Patency</measure>
    <time_frame>30 Days</time_frame>
    <description>Kaplan-Meier estimate of secondary patency at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Secondary Patency</measure>
    <time_frame>9 Months</time_frame>
    <description>Kaplan-Meier estimate of secondary patency at 9 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Freedom From Target Lesion Revascularization (TLR)</measure>
    <time_frame>30 Days</time_frame>
    <description>Kaplan-Meier estimate of freedom from target lesion revascularization (TLR) at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Freedom From Target Lesion Revascularization (TLR)</measure>
    <time_frame>9 Months</time_frame>
    <description>Kaplan-Meier estimate of freedom from target lesion revascularization (TLR) at 9 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Freedom From Clinically-Driven Target Lesion Revascularization (CD-TLR)</measure>
    <time_frame>30 Days</time_frame>
    <description>Kaplan-Meier estimate of freedom from clinically-driven target lesion revascularization (CD-TLR) at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Freedom From Clinically-Driven Target Lesion Revascularization (CD-TLR)</measure>
    <time_frame>9 Months</time_frame>
    <description>Kaplan-Meier estimate of freedom from clinically-driven target lesion revascularization (CD-TLR) at 9 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Freedom From Target Vessel Revascularization (TVR)</measure>
    <time_frame>30 Days</time_frame>
    <description>Kaplan-Meier estimate of freedom from target vessel revascularization (TVR) at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Freedom From Target Vessel Revascularization (TVR)</measure>
    <time_frame>9 Months</time_frame>
    <description>Kaplan-Meier estimate of freedom from target vessel revascularization (TVR) at 9 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Freedom From Clinically-Driven Target Vessel Revascularization (CD-TVR)</measure>
    <time_frame>30 Days</time_frame>
    <description>Kaplan-Meier estimate of freedom from clinically-driven target vessel revascularization (CD-TVR) at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Freedom From Clinically-Driven Target Vessel Revascularization (CD-TVR)</measure>
    <time_frame>9 Months</time_frame>
    <description>Kaplan-Meier estimate of freedom from clinically-driven target vessel revascularization (CD-TVR) at 9 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Rutherford Category</measure>
    <time_frame>30 Days</time_frame>
    <description>Number of participants with change in Rutherford Category from pre-procedure at 30 days.
Rutherford Categories:
Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.
Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Rutherford Category</measure>
    <time_frame>9 Months</time_frame>
    <description>Number of participants with change in Rutherford Category from pre-procedure at 9 months.
Rutherford Categories:
Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.
Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ankle Brachial Index (ABI)</measure>
    <time_frame>30 Days</time_frame>
    <description>Ankle brachial Index (ABI) is a common assessment of peripheral artery disease (PAD) and is obtained by comparing the systolic blood pressure of the legs to the systolic blood pressure of the arms. A normal resting ABI is .9 to 1.3. A resting ABI of less than .9 is abnormal. An outcome of a mean ABI above .9 and below 1.3 is considered a success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ankle Brachial Index (ABI)</measure>
    <time_frame>9 Months</time_frame>
    <description>Ankle brachial Index (ABI) is a common assessment of peripheral artery disease (PAD) and is obtained by comparing the systolic blood pressure of the legs to the systolic blood pressure of the arms. A normal resting ABI is .9 to 1.3. A resting ABI of less than .9 is abnormal. An outcome of a mean ABI above .9 and below 1.3 is considered a success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Mobility</measure>
    <time_frame>30 Days</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Mobility) from pre-procedure at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Mobility</measure>
    <time_frame>9 Months</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in Functional Status (EQ5D - Mobility) from pre-procedure at 9 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Self Care</measure>
    <time_frame>30 Days</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Self Care) from pre-procedure at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Self Care</measure>
    <time_frame>9 Months</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in Functional Status (EQ5D - Self Care) from pre-procedure at 9 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Usual Activities</measure>
    <time_frame>30 Days</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Usual Activities) from pre-procedure at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Usual Activities</measure>
    <time_frame>9 Months</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Usual Activities) from pre-procedure at 9 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Pain/Discomfort</measure>
    <time_frame>30 Days</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Pain/Discomfort) from pre-procedure at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Pain/Discomfort</measure>
    <time_frame>9 Months</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Pain/Discomfort) from pre-procedure at 9 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Anxiety/Depression</measure>
    <time_frame>30 Days</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Anxiety/Depression) from pre-procedure at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Anxiety/Depression</measure>
    <time_frame>9 Months</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Anxiety/Depression) from pre-procedure at 9 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Own Health State</measure>
    <time_frame>30 Days</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Own Health State) from pre-procedure at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Own Health State</measure>
    <time_frame>9 Months</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Own Health State) from pre-procedure at 9 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Improvement in Functional Status at 30 Days - Walking Improvement Questionnaire (WIQ)</measure>
    <time_frame>30 Days</time_frame>
    <description>Patient reported outcome based on study questionnaire. Percentage of subjects with improvement on WIQ from pre-procedure at 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Improvement in Functional Status 9 Months - Walking Improvement Questionnaire (WIQ)</measure>
    <time_frame>9 Months</time_frame>
    <description>Patient reported outcome based on study questionnaire. Percentage of subjects with improvement on WIQ from pre-procedure at 9 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Primary Patency</measure>
    <time_frame>12 Months</time_frame>
    <description>Kaplan-Meier estimate of primary patency at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Primary Assisted Patency</measure>
    <time_frame>12 Months</time_frame>
    <description>Kaplan-Meier estimate of primary assisted patency at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Secondary Patency</measure>
    <time_frame>12 Months</time_frame>
    <description>Kaplan-Meier estimate of secondary patency at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Freedom From Target Lesion Revascularization (TLR)</measure>
    <time_frame>12 Months</time_frame>
    <description>Kaplan-Meier estimate of freedom from target lesion revascularization (TLR) at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Freedom From Target Lesion Revascularization (TLR)</measure>
    <time_frame>24 Months</time_frame>
    <description>Kaplan-Meier estimate of freedom from target lesion revascularization (TLR) at 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Freedom From Target Lesion Revascularization (TLR)</measure>
    <time_frame>36 Months</time_frame>
    <description>Kaplan-Meier estimate of freedom from target lesion revascularization (TLR) at 36 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Freedom From Clinically-Driven Target Lesion Revascularization (CD-TLR)</measure>
    <time_frame>12 Months</time_frame>
    <description>Kaplan-Meier estimate of freedom from clinically-driven target lesion revascularization (CD-TLR) at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Freedom From Clinically-Driven Target Lesion Revascularization (CD-TLR)</measure>
    <time_frame>24 Months</time_frame>
    <description>Kaplan-Meier estimate of freedom from clinically-driven target lesion revascularization (CD-TLR) at 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Freedom From Clinically-Driven Target Lesion Revascularization (CD-TLR)</measure>
    <time_frame>36 Months</time_frame>
    <description>Kaplan-Meier estimate of freedom from clinically-driven target lesion revascularization (CD-TLR) at 36 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Freedom From Target Vessel Revascularization (TVR)</measure>
    <time_frame>12 Months</time_frame>
    <description>Kaplan-Meier estimate of freedom from target vessel revascularization (TVR) at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Freedom From Target Vessel Revascularization (TVR)</measure>
    <time_frame>24 Months</time_frame>
    <description>Kaplan-Meier estimate of freedom from target vessel revascularization (TVR) at 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Freedom From Target Vessel Revascularization (TVR)</measure>
    <time_frame>36 Months</time_frame>
    <description>Kaplan-Meier estimate of freedom from target vessel revascularization (TVR) at 36 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Freedom From Clinically-Driven Target Vessel Revascularization (CD-TVR)</measure>
    <time_frame>12 Months</time_frame>
    <description>Kaplan-Meier estimate of freedom from clinically-driven target vessel revascularization (CD-TVR) at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Freedom From Clinically-Driven Target Vessel Revascularization (CD-TVR)</measure>
    <time_frame>24 Months</time_frame>
    <description>Kaplan-Meier estimate of freedom from clinically-driven target vessel revascularization (CD-TVR) at 24 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Freedom From Clinically-Driven Target Vessel Revascularization (CD-TVR)</measure>
    <time_frame>36 Months</time_frame>
    <description>Kaplan-Meier estimate of freedom from clinically-driven target vessel revascularization (CD-TVR) at 36 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Rutherford Category</measure>
    <time_frame>12 Months</time_frame>
    <description>Number of participants with change in Rutherford Category from pre-procedure at 12 months.
Rutherford Categories:
Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.
Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Rutherford Category</measure>
    <time_frame>24 Months</time_frame>
    <description>Number of participants with change in Rutherford Category from pre-procedure at 24 months.
Rutherford Categories:
Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.
Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Rutherford Category</measure>
    <time_frame>36 Months</time_frame>
    <description>Number of participants with change in Rutherford Category from pre-procedure at 36 months.
Rutherford Categories:
Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.
Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ankle Brachial Index (ABI)</measure>
    <time_frame>12 Months</time_frame>
    <description>Ankle brachial Index (ABI) is a common assessment of peripheral artery disease (PAD) and is obtained by comparing the systolic blood pressure of the legs to the systolic blood pressure of the arms. A normal resting ABI is .9 to 1.3. A resting ABI of less than .9 is abnormal. An outcome of a mean ABI above .9 and below 1.3 is considered a success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ankle Brachial Index (ABI)</measure>
    <time_frame>24 Months</time_frame>
    <description>Ankle brachial Index (ABI) is a common assessment of peripheral artery disease (PAD) and is obtained by comparing the systolic blood pressure of the legs to the systolic blood pressure of the arms. A normal resting ABI is .9 to 1.3. A resting ABI of less than .9 is abnormal. An outcome of a mean ABI above .9 and below 1.3 is considered a success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ankle Brachial Index (ABI)</measure>
    <time_frame>36 Months</time_frame>
    <description>Ankle brachial Index (ABI) is a common assessment of peripheral artery disease (PAD) and is obtained by comparing the systolic blood pressure of the legs to the systolic blood pressure of the arms. A normal resting ABI is .9 to 1.3. A resting ABI of less than .9 is abnormal. An outcome of a mean ABI above .9 and below 1.3 is considered a success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Mobility</measure>
    <time_frame>12 Months</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in Functional Status (EQ5D - Mobility) from pre-procedure at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Mobility</measure>
    <time_frame>24 Months</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in Functional Status (EQ5D - Mobility) from pre-procedure at 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Mobility</measure>
    <time_frame>36 Months</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in Functional Status (EQ5D - Mobility) from pre-procedure at 36 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Self Care</measure>
    <time_frame>12 Months</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in Functional Status (EQ5D - Self Care) from pre-procedure at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Self Care</measure>
    <time_frame>24 Months</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in Functional Status (EQ5D - Self Care) from pre-procedure at 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Self Care</measure>
    <time_frame>36 Months</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in Functional Status (EQ5D - Self Care) from pre-procedure at 36 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Usual Activities</measure>
    <time_frame>12 Months</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Usual Activities) from pre-procedure at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Usual Activities</measure>
    <time_frame>24 Months</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Usual Activities) from pre-procedure at 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Usual Activities</measure>
    <time_frame>36 Months</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Usual Activities) from pre-procedure at 36 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Pain/Discomfort</measure>
    <time_frame>12 Months</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Pain/Discomfort) from pre-procedure at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Pain/Discomfort</measure>
    <time_frame>24 Months</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Pain/Discomfort) from pre-procedure at 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Pain/Discomfort</measure>
    <time_frame>36 Months</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Pain/Discomfort) from pre-procedure at 36 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Anxiety/Depression</measure>
    <time_frame>12 Months</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Anxiety/Depression) from pre-procedure at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Anxiety/Depression</measure>
    <time_frame>24 Months</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Anxiety/Depression) from pre-procedure at 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Anxiety/Depression</measure>
    <time_frame>36 Months</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Anxiety/Depression) from pre-procedure at 36 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Own Health State</measure>
    <time_frame>12 Months</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Own Health State) from pre-procedure at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Own Health State</measure>
    <time_frame>24 Months</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Own Health State) from pre-procedure at 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Change in Functional Status - EQ5D - Own Health State</measure>
    <time_frame>36 Months</time_frame>
    <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Own Health State) from pre-procedure at 36 months.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Device or Procedure-related Death</measure>
    <time_frame>30 Days</time_frame>
    <description>Number of subjects experiencing a device or procedure-related death within 30 Days - Component of primary outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Myocardial Infarction (MI)</measure>
    <time_frame>30 Days</time_frame>
    <description>Number of subjects experiencing a myocardial infarction (MI) within 30 Days - Component of primary outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Target Lesion Revascularization (TLR)</measure>
    <time_frame>9 Months</time_frame>
    <description>Number of subjects experiencing a target lesion revascularization (TLR) within 9 months - Component of primary outcome</description>
  </other_outcome>
  <other_outcome>
    <measure>Major Amputation</measure>
    <time_frame>9 Months</time_frame>
    <description>Number of subjects experiencing a major amputation of the target limb within 9 months - Component of primary outcome</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>Gore VIABAHN BX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Balloon expandable stenting of iliac occlusive disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stenting of the Common and/or External Iliac Arteries</intervention_name>
    <description>Balloon expandable stenting of iliac occlusive disease.</description>
    <arm_group_label>Gore VIABAHN BX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is at least 18 years old;

          2. Patient is male, infertile female, or female of childbearing potential practicing an
             acceptable method of preventing pregnancy;

          3. Patient or legal representative is willing to give written informed consent;

          4. Patient is capable of complying with protocol requirements, including all follow-up
             visits;

          5. Patient has symptomatic claudication or rest pain without tissue loss (Rutherford
             Categories 2-4).

          6. Patient has de novo or restenotic target lesion(s) in the common and/or external iliac
             artery;

          7. Patient has one or more regions of stenosis ≥ 50% in the target vessel, based on
             visual estimate;

          8. Patient has a target vessel diameter visually estimated to be approximately between 5
             mm and 13 mm;

          9. Patient has adequate ipsilateral blood flow including at least one sufficient (&lt;50%
             stenotic) infrapopliteal run-off vessel not requiring intervention (per side to be
             intervened on).

         10. Patient has a total target lesion length visually estimated to be ≤110 mm which can be
             treated with a maximum of three VIABAHN BX endoprostheses;

         11. Patient has no more than two discrete ipsilateral lesions that can be treated with no
             more than three VIABAHN BX endoprostheses [OR] Patient has bilateral disease
             consisting of only one target lesion per side that can be treated with no more than a
             total of three VIABAHN BX endoprostheses;

         12. Patient has the device advanced across the target lesion(s) and positioned for
             deployment.

        Exclusion Criteria:

          1. Patient has a life expectancy of less than 1 year;

          2. Patient has a known allergy to stent graft components, including stainless steel or
             heparin;

          3. Patient has a known intolerance to antiplatelet, anticoagulant, or thrombolytic
             medications that would prevent compliance with the protocol;

          4. Patient has a condition (unrelated to the study) that is expected to require
             indefinite, or lifelong, anticoagulation

          5. Patient has an uncorrected bleeding disorder (platelet count &lt; 80,000/µL);

          6. Patient has severe chronic renal insufficiency (serum creatinine level &gt; 2.5mg/dL) and
             not on hemodialysis;

          7. Patient has a known hypercoagulability that cannot be corrected;

          8. Patient has evidence of a blood borne infection;

          9. Patient has had vascular access/catheterization in the lower extremity within 30 days
             of study enrollment;

         10. Patient has had a previous or planned coronary intervention within 30 days prior to
             enrollment in this study or required at time of study procedure;

         11. Patient has had a previous or planned bypass surgery in the target leg, or a bypass
             that occurs at the time of the index procedure;

         12. Patient is currently participating in this or another investigative clinical study.

         13. Patient has a stent or stent graft located within or immediately adjacent (≤5mm) to
             study lesion(s);

         14. Patient has evidence of angiographically visible thrombus within or adjacent to the
             target lesion(s);

         15. Patient has aneurysmal dilation proximal or distal to the target lesion(s) that would
             interfere with the placement of the device;

         16. Patient has a target lesion requiring atherectomy or any ablative device to facilitate
             stent delivery;

         17. Patient has a target lesion situated in such a way that an implanted device will
             prevent blood flow or perfusion to the internal iliac artery if patent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Bismuth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Methodist Hospital System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Luke's Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Health Research Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20782</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Cardiac and Vascular Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Vascular Institute</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Associates</name>
      <address>
        <city>Elk Grove Village</city>
        <state>Illinois</state>
        <zip>60007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Methodist Medical Center</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Essentia Institute for Rural Health / St Mary's Hospital</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Memorial Heart &amp; Vascular Institute</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Vascular Associates</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Name Medical Center</name>
      <address>
        <city>Teaneck</city>
        <state>New Jersey</state>
        <zip>07666</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Foundation SUNY Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Clinic - Clinical Research</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio Health</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Spirit Cardiovascular Institute</name>
      <address>
        <city>Camp Hill</city>
        <state>Pennsylvania</state>
        <zip>17011</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Miriam Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02906</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUSC</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Memorial Hospital</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Surgical Associates</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellmont Holston Valley Medical Center</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Medical Group</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland City Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>March 4, 2014</study_first_submitted>
  <study_first_submitted_qc>March 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2014</study_first_posted>
  <results_first_submitted>June 2, 2017</results_first_submitted>
  <results_first_submitted_qc>July 13, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">July 17, 2018</results_first_posted>
  <last_update_submitted>December 27, 2018</last_update_submitted>
  <last_update_submitted_qc>December 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PAD</keyword>
  <keyword>Stent</keyword>
  <keyword>Claudication</keyword>
  <keyword>Viabahn</keyword>
  <keyword>Gore</keyword>
  <keyword>Endoprosthesis</keyword>
  <keyword>Vascular Diseases</keyword>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Iliac Occlusive Disease</keyword>
  <keyword>Balloon Expandable</keyword>
  <keyword>Stent-graft</keyword>
  <keyword>VBX</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Gore VIABAHN BX</title>
          <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="134"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="132"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Iliac Stenting</title>
          <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="134"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Adults &gt;/= 18 years</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Composite of Major Adverse Events (MAEs)</title>
        <description>Percentage of study subjects experiencing a major adverse event (MAE) defined as: device or procedure-related death within 30 days, myocardial infarction (MI) within 30 days, target lesion revascularization (TLR) within 9 months or major amputation of the target limb within 9 months.</description>
        <time_frame>9 months</time_frame>
        <population>Population includes enrolled subjects who either experienced the defined event or were followed for at least 240 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite of Major Adverse Events (MAEs)</title>
          <description>Percentage of study subjects experiencing a major adverse event (MAE) defined as: device or procedure-related death within 30 days, myocardial infarction (MI) within 30 days, target lesion revascularization (TLR) within 9 months or major amputation of the target limb within 9 months.</description>
          <population>Population includes enrolled subjects who either experienced the defined event or were followed for at least 240 days.</population>
          <units>percentage of subjects experiencing MAE</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" lower_limit="0.5" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The sample size obtains over 90% power to statistically show the probability that a subject will experience an MAE with use of the study device is less than 17% when 12% or less of the subjects are lost to follow up prior to 9 months.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>This was a single-arm study designed to compare the primary outcome result to a performance goal based on published literature. The null hypothesis was the probability of a subject experiencing a Major Adverse Event (MAE) with use of study device is at least 17%. The alternate hypothesis was the probability of a subject experiencing a Major Adverse Event (MAE) with use of the study device is less than 17%.</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <method>one-sided binomial exact test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Procedural Success</title>
        <description>Number of subjects who experienced Acute Procedural Success defined as less than or equal to 30% residual stenosis prior to procedure completion and no device- or procedure-related SAEs before discharge.</description>
        <time_frame>Discharge</time_frame>
        <population>Population includes subjects followed through discharge and had relevant procedural data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Procedural Success</title>
          <description>Number of subjects who experienced Acute Procedural Success defined as less than or equal to 30% residual stenosis prior to procedure completion and no device- or procedure-related SAEs before discharge.</description>
          <population>Population includes subjects followed through discharge and had relevant procedural data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>30-Day Clinical Success</title>
        <description>Number of subjects who experienced 30-Day Clinical Success defined as an improvement of at least one Rutherford Category at the 30-day visit as compared to pre-procedure and no device- or procedure-related SAEs within 30 days of the index procedure.</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes subjects followed for at least 30 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>30-Day Clinical Success</title>
          <description>Number of subjects who experienced 30-Day Clinical Success defined as an improvement of at least one Rutherford Category at the 30-day visit as compared to pre-procedure and no device- or procedure-related SAEs within 30 days of the index procedure.</description>
          <population>Population includes subjects followed for at least 30 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Primary Patency</title>
        <description>Kaplan-Meier estimate of primary patency at 30 days.</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes all subjects meeting eligibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Primary Patency</title>
          <description>Kaplan-Meier estimate of primary patency at 30 days.</description>
          <population>Population includes all subjects meeting eligibility.</population>
          <units>survival percentage by subject</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" lower_limit="94.8" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Primary Patency</title>
        <description>Kaplan-Meier estimate of primary patency at 9 months.</description>
        <time_frame>9 Months</time_frame>
        <population>Population includes all subjects meeting eligibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Primary Patency</title>
          <description>Kaplan-Meier estimate of primary patency at 9 months.</description>
          <population>Population includes all subjects meeting eligibility.</population>
          <units>survival percentage by subject</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.7" lower_limit="91.5" upper_limit="98.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Primary Assisted Patency</title>
        <description>Kaplan-Meier estimate of primary assisted patency at 30 days.</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes all subjects meeting eligibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Primary Assisted Patency</title>
          <description>Kaplan-Meier estimate of primary assisted patency at 30 days.</description>
          <population>Population includes all subjects meeting eligibility.</population>
          <units>survival percentage by subject</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" lower_limit="94.8" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Primary Assisted Patency</title>
        <description>Kaplan-Meier estimate of primary assisted patency at 9 months.</description>
        <time_frame>9 Months</time_frame>
        <population>Population includes all subjects meeting eligibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Primary Assisted Patency</title>
          <description>Kaplan-Meier estimate of primary assisted patency at 9 months.</description>
          <population>Population includes all subjects meeting eligibility.</population>
          <units>survival percentage by subject</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" lower_limit="94.8" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Secondary Patency</title>
        <description>Kaplan-Meier estimate of secondary patency at 30 days.</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes all subjects meeting eligibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Secondary Patency</title>
          <description>Kaplan-Meier estimate of secondary patency at 30 days.</description>
          <population>Population includes all subjects meeting eligibility.</population>
          <units>survival percentage by subject</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" lower_limit="94.8" upper_limit="99.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Secondary Patency</title>
        <description>Kaplan-Meier estimate of secondary patency at 9 months.</description>
        <time_frame>9 Months</time_frame>
        <population>Population includes all subjects meeting eligibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Secondary Patency</title>
          <description>Kaplan-Meier estimate of secondary patency at 9 months.</description>
          <population>Population includes all subjects meeting eligibility.</population>
          <units>survival percentage by subject</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" lower_limit="94.8" upper_limit="99.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Freedom From Target Lesion Revascularization (TLR)</title>
        <description>Kaplan-Meier estimate of freedom from target lesion revascularization (TLR) at 30 days.</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes all subjects meeting eligibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Freedom From Target Lesion Revascularization (TLR)</title>
          <description>Kaplan-Meier estimate of freedom from target lesion revascularization (TLR) at 30 days.</description>
          <population>Population includes all subjects meeting eligibility.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Freedom From Target Lesion Revascularization (TLR)</title>
        <description>Kaplan-Meier estimate of freedom from target lesion revascularization (TLR) at 9 months.</description>
        <time_frame>9 Months</time_frame>
        <population>Population includes all subjects meeting eligibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Freedom From Target Lesion Revascularization (TLR)</title>
          <description>Kaplan-Meier estimate of freedom from target lesion revascularization (TLR) at 9 months.</description>
          <population>Population includes all subjects meeting eligibility.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" lower_limit="92.9" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Freedom From Clinically-Driven Target Lesion Revascularization (CD-TLR)</title>
        <description>Kaplan-Meier estimate of freedom from clinically-driven target lesion revascularization (CD-TLR) at 30 days.</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes all subjects meeting eligibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Freedom From Clinically-Driven Target Lesion Revascularization (CD-TLR)</title>
          <description>Kaplan-Meier estimate of freedom from clinically-driven target lesion revascularization (CD-TLR) at 30 days.</description>
          <population>Population includes all subjects meeting eligibility.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Freedom From Clinically-Driven Target Lesion Revascularization (CD-TLR)</title>
        <description>Kaplan-Meier estimate of freedom from clinically-driven target lesion revascularization (CD-TLR) at 9 months.</description>
        <time_frame>9 Months</time_frame>
        <population>Population includes all subjects meeting eligibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Freedom From Clinically-Driven Target Lesion Revascularization (CD-TLR)</title>
          <description>Kaplan-Meier estimate of freedom from clinically-driven target lesion revascularization (CD-TLR) at 9 months.</description>
          <population>Population includes all subjects meeting eligibility.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4" lower_limit="93.8" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Freedom From Target Vessel Revascularization (TVR)</title>
        <description>Kaplan-Meier estimate of freedom from target vessel revascularization (TVR) at 30 days.</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes all subjects meeting eligibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Freedom From Target Vessel Revascularization (TVR)</title>
          <description>Kaplan-Meier estimate of freedom from target vessel revascularization (TVR) at 30 days.</description>
          <population>Population includes all subjects meeting eligibility.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Freedom From Target Vessel Revascularization (TVR)</title>
        <description>Kaplan-Meier estimate of freedom from target vessel revascularization (TVR) at 9 months.</description>
        <time_frame>9 Months</time_frame>
        <population>Population includes all subjects meeting eligibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Freedom From Target Vessel Revascularization (TVR)</title>
          <description>Kaplan-Meier estimate of freedom from target vessel revascularization (TVR) at 9 months.</description>
          <population>Population includes all subjects meeting eligibility.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" lower_limit="92.9" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Freedom From Clinically-Driven Target Vessel Revascularization (CD-TVR)</title>
        <description>Kaplan-Meier estimate of freedom from clinically-driven target vessel revascularization (CD-TVR) at 30 days.</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes all subjects meeting eligibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Freedom From Clinically-Driven Target Vessel Revascularization (CD-TVR)</title>
          <description>Kaplan-Meier estimate of freedom from clinically-driven target vessel revascularization (CD-TVR) at 30 days.</description>
          <population>Population includes all subjects meeting eligibility.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Freedom From Clinically-Driven Target Vessel Revascularization (CD-TVR)</title>
        <description>Kaplan-Meier estimate of freedom from clinically-driven target vessel revascularization (CD-TVR) at 9 months</description>
        <time_frame>9 Months</time_frame>
        <population>Population includes all subjects meeting eligibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Freedom From Clinically-Driven Target Vessel Revascularization (CD-TVR)</title>
          <description>Kaplan-Meier estimate of freedom from clinically-driven target vessel revascularization (CD-TVR) at 9 months</description>
          <population>Population includes all subjects meeting eligibility.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" lower_limit="92.9" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Rutherford Category</title>
        <description>Number of participants with change in Rutherford Category from pre-procedure at 30 days.
Rutherford Categories:
Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.
Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes subjects followed for at least 23 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Rutherford Category</title>
          <description>Number of participants with change in Rutherford Category from pre-procedure at 30 days.
Rutherford Categories:
Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.
Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene</description>
          <population>Population includes subjects followed for at least 23 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="118"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved Rutherford Category</title>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained Rutherford Category</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened Rutherford Category</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Rutherford Category</title>
        <description>Number of participants with change in Rutherford Category from pre-procedure at 9 months.
Rutherford Categories:
Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.
Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene</description>
        <time_frame>9 Months</time_frame>
        <population>Population includes subjects followed for at least 240 days and relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Rutherford Category</title>
          <description>Number of participants with change in Rutherford Category from pre-procedure at 9 months.
Rutherford Categories:
Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.
Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene</description>
          <population>Population includes subjects followed for at least 240 days and relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved Rutherford Category</title>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained Rutherford Category</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened Rutherford Category</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ankle Brachial Index (ABI)</title>
        <description>Ankle brachial Index (ABI) is a common assessment of peripheral artery disease (PAD) and is obtained by comparing the systolic blood pressure of the legs to the systolic blood pressure of the arms. A normal resting ABI is .9 to 1.3. A resting ABI of less than .9 is abnormal. An outcome of a mean ABI above .9 and below 1.3 is considered a success.</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes subjects followed for at least 23 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ankle Brachial Index (ABI)</title>
          <description>Ankle brachial Index (ABI) is a common assessment of peripheral artery disease (PAD) and is obtained by comparing the systolic blood pressure of the legs to the systolic blood pressure of the arms. A normal resting ABI is .9 to 1.3. A resting ABI of less than .9 is abnormal. An outcome of a mean ABI above .9 and below 1.3 is considered a success.</description>
          <population>Population includes subjects followed for at least 23 days and had relevant data.</population>
          <units>ratio index</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="174"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".97" lower_limit=".42" upper_limit="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ankle Brachial Index (ABI)</title>
        <description>Ankle brachial Index (ABI) is a common assessment of peripheral artery disease (PAD) and is obtained by comparing the systolic blood pressure of the legs to the systolic blood pressure of the arms. A normal resting ABI is .9 to 1.3. A resting ABI of less than .9 is abnormal. An outcome of a mean ABI above .9 and below 1.3 is considered a success.</description>
        <time_frame>9 Months</time_frame>
        <population>Population includes subjects followed for at least 240 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ankle Brachial Index (ABI)</title>
          <description>Ankle brachial Index (ABI) is a common assessment of peripheral artery disease (PAD) and is obtained by comparing the systolic blood pressure of the legs to the systolic blood pressure of the arms. A normal resting ABI is .9 to 1.3. A resting ABI of less than .9 is abnormal. An outcome of a mean ABI above .9 and below 1.3 is considered a success.</description>
          <population>Population includes subjects followed for at least 240 days and had relevant data.</population>
          <units>ratio index</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="169"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" lower_limit=".42" upper_limit="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Mobility</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Mobility) from pre-procedure at 30 days.</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes subjects followed for at least 23 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Mobility</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Mobility) from pre-procedure at 30 days.</description>
          <population>Population includes subjects followed for at least 23 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Mobility</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in Functional Status (EQ5D - Mobility) from pre-procedure at 9 months.</description>
        <time_frame>9 Months</time_frame>
        <population>Population includes subjects followed for at least 240 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Mobility</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in Functional Status (EQ5D - Mobility) from pre-procedure at 9 months.</description>
          <population>Population includes subjects followed for at least 240 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Self Care</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Self Care) from pre-procedure at 30 days.</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes subjects followed for at least 30 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Self Care</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Self Care) from pre-procedure at 30 days.</description>
          <population>Population includes subjects followed for at least 30 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Self Care</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in Functional Status (EQ5D - Self Care) from pre-procedure at 9 months.</description>
        <time_frame>9 Months</time_frame>
        <population>Population includes subjects followed for at least 240 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Self Care</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in Functional Status (EQ5D - Self Care) from pre-procedure at 9 months.</description>
          <population>Population includes subjects followed for at least 240 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="105"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Usual Activities</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Usual Activities) from pre-procedure at 30 days.</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes subjects followed for at least 30 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Usual Activities</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Usual Activities) from pre-procedure at 30 days.</description>
          <population>Population includes subjects followed for at least 30 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Usual Activities</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Usual Activities) from pre-procedure at 9 months.</description>
        <time_frame>9 Months</time_frame>
        <population>Population includes subjects followed for at least 240 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Usual Activities</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Usual Activities) from pre-procedure at 9 months.</description>
          <population>Population includes subjects followed for at least 240 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Pain/Discomfort</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Pain/Discomfort) from pre-procedure at 30 days.</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes subjects followed for at least 30 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Pain/Discomfort</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Pain/Discomfort) from pre-procedure at 30 days.</description>
          <population>Population includes subjects followed for at least 30 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Pain/Discomfort</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Pain/Discomfort) from pre-procedure at 9 months.</description>
        <time_frame>9 Months</time_frame>
        <population>Population includes subjects followed for at least 240 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Pain/Discomfort</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Pain/Discomfort) from pre-procedure at 9 months.</description>
          <population>Population includes subjects followed for at least 240 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Anxiety/Depression</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Anxiety/Depression) from pre-procedure at 30 days.</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes subjects followed for at least 30 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Anxiety/Depression</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Anxiety/Depression) from pre-procedure at 30 days.</description>
          <population>Population includes subjects followed for at least 30 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Anxiety/Depression</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Anxiety/Depression) from pre-procedure at 9 months.</description>
        <time_frame>9 Months</time_frame>
        <population>Population includes subjects followed for at least 240 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Anxiety/Depression</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Anxiety/Depression) from pre-procedure at 9 months.</description>
          <population>Population includes subjects followed for at least 240 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Own Health State</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Own Health State) from pre-procedure at 30 days.</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes subjects followed for at least 30 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Own Health State</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Own Health State) from pre-procedure at 30 days.</description>
          <population>Population includes subjects followed for at least 30 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Own Health State</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Own Health State) from pre-procedure at 9 months.</description>
        <time_frame>9 Months</time_frame>
        <population>Population includes subjects followed for at least 240 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Own Health State</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Own Health State) from pre-procedure at 9 months.</description>
          <population>Population includes subjects followed for at least 240 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Improvement in Functional Status at 30 Days - Walking Improvement Questionnaire (WIQ)</title>
        <description>Patient reported outcome based on study questionnaire. Percentage of subjects with improvement on WIQ from pre-procedure at 30 days.</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes subjects followed for at least 30 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Improvement in Functional Status at 30 Days - Walking Improvement Questionnaire (WIQ)</title>
          <description>Patient reported outcome based on study questionnaire. Percentage of subjects with improvement on WIQ from pre-procedure at 30 days.</description>
          <population>Population includes subjects followed for at least 30 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Improvement in Functional Status 9 Months - Walking Improvement Questionnaire (WIQ)</title>
        <description>Patient reported outcome based on study questionnaire. Percentage of subjects with improvement on WIQ from pre-procedure at 9 months.</description>
        <time_frame>9 Months</time_frame>
        <population>Population includes subjects followed for at least 240 days and had relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Improvement in Functional Status 9 Months - Walking Improvement Questionnaire (WIQ)</title>
          <description>Patient reported outcome based on study questionnaire. Percentage of subjects with improvement on WIQ from pre-procedure at 9 months.</description>
          <population>Population includes subjects followed for at least 240 days and had relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Primary Patency</title>
        <description>Kaplan-Meier estimate of primary patency at 12 months.</description>
        <time_frame>12 Months</time_frame>
        <population>Population includes all subjects meeting eligibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Primary Patency</title>
          <description>Kaplan-Meier estimate of primary patency at 12 months.</description>
          <population>Population includes all subjects meeting eligibility.</population>
          <units>survival percentage by subject</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.4" lower_limit="88.7" upper_limit="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Primary Assisted Patency</title>
        <description>Kaplan-Meier estimate of primary assisted patency at 12 months.</description>
        <time_frame>12 Months</time_frame>
        <population>Population includes all subjects meeting eligibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Primary Assisted Patency</title>
          <description>Kaplan-Meier estimate of primary assisted patency at 12 months.</description>
          <population>Population includes all subjects meeting eligibility.</population>
          <units>survival percentage by subject</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.4" lower_limit="93.9" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Secondary Patency</title>
        <description>Kaplan-Meier estimate of secondary patency at 12 months.</description>
        <time_frame>12 Months</time_frame>
        <population>Population includes all subjects meeting eligibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Secondary Patency</title>
          <description>Kaplan-Meier estimate of secondary patency at 12 months.</description>
          <population>Population includes all subjects meeting eligibility.</population>
          <units>survival percentage by subject</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.2" lower_limit="94.8" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Freedom From Target Lesion Revascularization (TLR)</title>
        <description>Kaplan-Meier estimate of freedom from target lesion revascularization (TLR) at 12 months.</description>
        <time_frame>12 Months</time_frame>
        <population>Population includes all subjects meeting eligibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Freedom From Target Lesion Revascularization (TLR)</title>
          <description>Kaplan-Meier estimate of freedom from target lesion revascularization (TLR) at 12 months.</description>
          <population>Population includes all subjects meeting eligibility.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.4" lower_limit="90.1" upper_limit="97.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Freedom From Target Lesion Revascularization (TLR)</title>
        <description>Kaplan-Meier estimate of freedom from target lesion revascularization (TLR) at 24 months.</description>
        <time_frame>24 Months</time_frame>
        <population>Population includes all subjects meeting eligibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Freedom From Target Lesion Revascularization (TLR)</title>
          <description>Kaplan-Meier estimate of freedom from target lesion revascularization (TLR) at 24 months.</description>
          <population>Population includes all subjects meeting eligibility.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.1" lower_limit="87.1" upper_limit="96.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Freedom From Target Lesion Revascularization (TLR)</title>
        <description>Kaplan-Meier estimate of freedom from target lesion revascularization (TLR) at 36 months.</description>
        <time_frame>36 Months</time_frame>
        <population>Population includes all subjects meeting eligibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Freedom From Target Lesion Revascularization (TLR)</title>
          <description>Kaplan-Meier estimate of freedom from target lesion revascularization (TLR) at 36 months.</description>
          <population>Population includes all subjects meeting eligibility.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.4" lower_limit="84.9" upper_limit="95.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Freedom From Clinically-Driven Target Lesion Revascularization (CD-TLR)</title>
        <description>Kaplan-Meier estimate of freedom from clinically-driven target lesion revascularization (CD-TLR) at 12 months.</description>
        <time_frame>12 Months</time_frame>
        <population>Population includes all subjects meeting eligibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Freedom From Clinically-Driven Target Lesion Revascularization (CD-TLR)</title>
          <description>Kaplan-Meier estimate of freedom from clinically-driven target lesion revascularization (CD-TLR) at 12 months.</description>
          <population>Population includes all subjects meeting eligibility.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" lower_limit="93.1" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Freedom From Clinically-Driven Target Lesion Revascularization (CD-TLR)</title>
        <description>Kaplan-Meier estimate of freedom from clinically-driven target lesion revascularization (CD-TLR) at 24 months.</description>
        <time_frame>24 Months</time_frame>
        <population>Population includes all subjects meeting eligibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Freedom From Clinically-Driven Target Lesion Revascularization (CD-TLR)</title>
          <description>Kaplan-Meier estimate of freedom from clinically-driven target lesion revascularization (CD-TLR) at 24 months.</description>
          <population>Population includes all subjects meeting eligibility.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" lower_limit="93.1" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Freedom From Clinically-Driven Target Lesion Revascularization (CD-TLR)</title>
        <description>Kaplan-Meier estimate of freedom from clinically-driven target lesion revascularization (CD-TLR) at 36 months.</description>
        <time_frame>36 Months</time_frame>
        <population>Population includes all subjects meeting eligibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Freedom From Clinically-Driven Target Lesion Revascularization (CD-TLR)</title>
          <description>Kaplan-Meier estimate of freedom from clinically-driven target lesion revascularization (CD-TLR) at 36 months.</description>
          <population>Population includes all subjects meeting eligibility.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" lower_limit="93.1" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Freedom From Target Vessel Revascularization (TVR)</title>
        <description>Kaplan-Meier estimate of freedom from target vessel revascularization (TVR) at 12 months.</description>
        <time_frame>12 Months</time_frame>
        <population>Population includes all subjects meeting eligibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Freedom From Target Vessel Revascularization (TVR)</title>
          <description>Kaplan-Meier estimate of freedom from target vessel revascularization (TVR) at 12 months.</description>
          <population>Population includes all subjects meeting eligibility.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.4" lower_limit="90.1" upper_limit="97.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Freedom From Target Vessel Revascularization (TVR)</title>
        <description>Kaplan-Meier estimate of freedom from target vessel revascularization (TVR) at 24 months.</description>
        <time_frame>24 Months</time_frame>
        <population>Population includes all subjects meeting eligibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Freedom From Target Vessel Revascularization (TVR)</title>
          <description>Kaplan-Meier estimate of freedom from target vessel revascularization (TVR) at 24 months.</description>
          <population>Population includes all subjects meeting eligibility.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3" lower_limit="86.1" upper_limit="95.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Freedom From Target Vessel Revascularization (TVR)</title>
        <description>Kaplan-Meier estimate of freedom from target vessel revascularization (TVR) at 36 months.</description>
        <time_frame>36 Months</time_frame>
        <population>Population includes all subjects meeting eligibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Freedom From Target Vessel Revascularization (TVR)</title>
          <description>Kaplan-Meier estimate of freedom from target vessel revascularization (TVR) at 36 months.</description>
          <population>Population includes all subjects meeting eligibility.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.6" lower_limit="84.0" upper_limit="94.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Freedom From Clinically-Driven Target Vessel Revascularization (CD-TVR)</title>
        <description>Kaplan-Meier estimate of freedom from clinically-driven target vessel revascularization (CD-TVR) at 12 months</description>
        <time_frame>12 Months</time_frame>
        <population>Population includes all subjects meeting eligibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Freedom From Clinically-Driven Target Vessel Revascularization (CD-TVR)</title>
          <description>Kaplan-Meier estimate of freedom from clinically-driven target vessel revascularization (CD-TVR) at 12 months</description>
          <population>Population includes all subjects meeting eligibility.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.7" lower_limit="93.1" upper_limit="99.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Freedom From Clinically-Driven Target Vessel Revascularization (CD-TVR)</title>
        <description>Kaplan-Meier estimate of freedom from clinically-driven target vessel revascularization (CD-TVR) at 24 months</description>
        <time_frame>24 Months</time_frame>
        <population>Population includes all subjects meeting eligibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Freedom From Clinically-Driven Target Vessel Revascularization (CD-TVR)</title>
          <description>Kaplan-Meier estimate of freedom from clinically-driven target vessel revascularization (CD-TVR) at 24 months</description>
          <population>Population includes all subjects meeting eligibility.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.9" lower_limit="92.0" upper_limit="98.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Freedom From Clinically-Driven Target Vessel Revascularization (CD-TVR)</title>
        <description>Kaplan-Meier estimate of freedom from clinically-driven target vessel revascularization (CD-TVR) at 36 months</description>
        <time_frame>36 Months</time_frame>
        <population>Population includes all subjects meeting eligibility.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Freedom From Clinically-Driven Target Vessel Revascularization (CD-TVR)</title>
          <description>Kaplan-Meier estimate of freedom from clinically-driven target vessel revascularization (CD-TVR) at 36 months</description>
          <population>Population includes all subjects meeting eligibility.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.1" lower_limit="90.9" upper_limit="98.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Rutherford Category</title>
        <description>Number of participants with change in Rutherford Category from pre-procedure at 12 months.
Rutherford Categories:
Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.
Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene</description>
        <time_frame>12 Months</time_frame>
        <population>Population includes subjects available at 12 Months with relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Rutherford Category</title>
          <description>Number of participants with change in Rutherford Category from pre-procedure at 12 months.
Rutherford Categories:
Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.
Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene</description>
          <population>Population includes subjects available at 12 Months with relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved Rutherford Category</title>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained Rutherford Category</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened Rutherford Category</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Rutherford Category</title>
        <description>Number of participants with change in Rutherford Category from pre-procedure at 24 months.
Rutherford Categories:
Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.
Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene</description>
        <time_frame>24 Months</time_frame>
        <population>Population includes subjects available at 24 Months with relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Rutherford Category</title>
          <description>Number of participants with change in Rutherford Category from pre-procedure at 24 months.
Rutherford Categories:
Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.
Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene</description>
          <population>Population includes subjects available at 24 Months with relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved Rutherford Category</title>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained Rutherford Category</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened Rutherford Category</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Rutherford Category</title>
        <description>Number of participants with change in Rutherford Category from pre-procedure at 36 months.
Rutherford Categories:
Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.
Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene</description>
        <time_frame>36 Months</time_frame>
        <population>Population includes subjects available at 36 Months with relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Rutherford Category</title>
          <description>Number of participants with change in Rutherford Category from pre-procedure at 36 months.
Rutherford Categories:
Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.
Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene</description>
          <population>Population includes subjects available at 36 Months with relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved Rutherford Category</title>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained Rutherford Category</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened Rutherford Category</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ankle Brachial Index (ABI)</title>
        <description>Ankle brachial Index (ABI) is a common assessment of peripheral artery disease (PAD) and is obtained by comparing the systolic blood pressure of the legs to the systolic blood pressure of the arms. A normal resting ABI is .9 to 1.3. A resting ABI of less than .9 is abnormal. An outcome of a mean ABI above .9 and below 1.3 is considered a success.</description>
        <time_frame>12 Months</time_frame>
        <population>Population includes subjects available at 12 Months with relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ankle Brachial Index (ABI)</title>
          <description>Ankle brachial Index (ABI) is a common assessment of peripheral artery disease (PAD) and is obtained by comparing the systolic blood pressure of the legs to the systolic blood pressure of the arms. A normal resting ABI is .9 to 1.3. A resting ABI of less than .9 is abnormal. An outcome of a mean ABI above .9 and below 1.3 is considered a success.</description>
          <population>Population includes subjects available at 12 Months with relevant data.</population>
          <units>ratio index</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>Limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" lower_limit="-.90" upper_limit=".82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ankle Brachial Index (ABI)</title>
        <description>Ankle brachial Index (ABI) is a common assessment of peripheral artery disease (PAD) and is obtained by comparing the systolic blood pressure of the legs to the systolic blood pressure of the arms. A normal resting ABI is .9 to 1.3. A resting ABI of less than .9 is abnormal. An outcome of a mean ABI above .9 and below 1.3 is considered a success.</description>
        <time_frame>24 Months</time_frame>
        <population>Population includes subjects available at 24 Months with relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ankle Brachial Index (ABI)</title>
          <description>Ankle brachial Index (ABI) is a common assessment of peripheral artery disease (PAD) and is obtained by comparing the systolic blood pressure of the legs to the systolic blood pressure of the arms. A normal resting ABI is .9 to 1.3. A resting ABI of less than .9 is abnormal. An outcome of a mean ABI above .9 and below 1.3 is considered a success.</description>
          <population>Population includes subjects available at 24 Months with relevant data.</population>
          <units>ratio index</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>Limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="117"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".17" lower_limit="-1.0" upper_limit="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Ankle Brachial Index (ABI)</title>
        <description>Ankle brachial Index (ABI) is a common assessment of peripheral artery disease (PAD) and is obtained by comparing the systolic blood pressure of the legs to the systolic blood pressure of the arms. A normal resting ABI is .9 to 1.3. A resting ABI of less than .9 is abnormal. An outcome of a mean ABI above .9 and below 1.3 is considered a success.</description>
        <time_frame>36 Months</time_frame>
        <population>Population includes subjects available at 36 Months with relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Ankle Brachial Index (ABI)</title>
          <description>Ankle brachial Index (ABI) is a common assessment of peripheral artery disease (PAD) and is obtained by comparing the systolic blood pressure of the legs to the systolic blood pressure of the arms. A normal resting ABI is .9 to 1.3. A resting ABI of less than .9 is abnormal. An outcome of a mean ABI above .9 and below 1.3 is considered a success.</description>
          <population>Population includes subjects available at 36 Months with relevant data.</population>
          <units>ratio index</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>Limbs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Limbs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" lower_limit="-0.40" upper_limit="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Mobility</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in Functional Status (EQ5D - Mobility) from pre-procedure at 12 months.</description>
        <time_frame>12 Months</time_frame>
        <population>Population includes subjects available at 12 months with relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Mobility</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in Functional Status (EQ5D - Mobility) from pre-procedure at 12 months.</description>
          <population>Population includes subjects available at 12 months with relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Mobility</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in Functional Status (EQ5D - Mobility) from pre-procedure at 24 months.</description>
        <time_frame>24 Months</time_frame>
        <population>Population includes subjects available at 24 months with relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Mobility</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in Functional Status (EQ5D - Mobility) from pre-procedure at 24 months.</description>
          <population>Population includes subjects available at 24 months with relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Mobility</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in Functional Status (EQ5D - Mobility) from pre-procedure at 36 months.</description>
        <time_frame>36 Months</time_frame>
        <population>Population includes subjects available at 36 months with relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Mobility</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in Functional Status (EQ5D - Mobility) from pre-procedure at 36 months.</description>
          <population>Population includes subjects available at 36 months with relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Self Care</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in Functional Status (EQ5D - Self Care) from pre-procedure at 12 months.</description>
        <time_frame>12 Months</time_frame>
        <population>Population includes subjects available at 12 months with relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Self Care</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in Functional Status (EQ5D - Self Care) from pre-procedure at 12 months.</description>
          <population>Population includes subjects available at 12 months with relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Self Care</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in Functional Status (EQ5D - Self Care) from pre-procedure at 24 months.</description>
        <time_frame>24 Months</time_frame>
        <population>Population includes subjects available at 24 months with relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Self Care</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in Functional Status (EQ5D - Self Care) from pre-procedure at 24 months.</description>
          <population>Population includes subjects available at 24 months with relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Self Care</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in Functional Status (EQ5D - Self Care) from pre-procedure at 36 months.</description>
        <time_frame>36 Months</time_frame>
        <population>Population includes subjects available at 36 months with relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Self Care</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in Functional Status (EQ5D - Self Care) from pre-procedure at 36 months.</description>
          <population>Population includes subjects available at 36 months with relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Usual Activities</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Usual Activities) from pre-procedure at 12 months.</description>
        <time_frame>12 Months</time_frame>
        <population>Population includes subjects available at 12 months with relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Usual Activities</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Usual Activities) from pre-procedure at 12 months.</description>
          <population>Population includes subjects available at 12 months with relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Usual Activities</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Usual Activities) from pre-procedure at 24 months.</description>
        <time_frame>24 Months</time_frame>
        <population>Population includes subjects available at 24 months with relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Usual Activities</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Usual Activities) from pre-procedure at 24 months.</description>
          <population>Population includes subjects available at 24 months with relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Usual Activities</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Usual Activities) from pre-procedure at 36 months.</description>
        <time_frame>36 Months</time_frame>
        <population>Population includes subjects available at 36 months with relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Usual Activities</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Usual Activities) from pre-procedure at 36 months.</description>
          <population>Population includes subjects available at 36 months with relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Pain/Discomfort</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Pain/Discomfort) from pre-procedure at 12 months.</description>
        <time_frame>12 Months</time_frame>
        <population>Population includes subjects available at 12 months with relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Pain/Discomfort</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Pain/Discomfort) from pre-procedure at 12 months.</description>
          <population>Population includes subjects available at 12 months with relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Pain/Discomfort</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Pain/Discomfort) from pre-procedure at 24 months.</description>
        <time_frame>24 Months</time_frame>
        <population>Population includes subjects available at 24 months with relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Pain/Discomfort</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Pain/Discomfort) from pre-procedure at 24 months.</description>
          <population>Population includes subjects available at 24 months with relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Device or Procedure-related Death</title>
        <description>Number of subjects experiencing a device or procedure-related death within 30 Days - Component of primary outcome</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes subjects followed for at least 30 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Device or Procedure-related Death</title>
          <description>Number of subjects experiencing a device or procedure-related death within 30 Days - Component of primary outcome</description>
          <population>Population includes subjects followed for at least 30 days.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Myocardial Infarction (MI)</title>
        <description>Number of subjects experiencing a myocardial infarction (MI) within 30 Days - Component of primary outcome</description>
        <time_frame>30 Days</time_frame>
        <population>Population includes subjects followed for at least 30 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Myocardial Infarction (MI)</title>
          <description>Number of subjects experiencing a myocardial infarction (MI) within 30 Days - Component of primary outcome</description>
          <population>Population includes subjects followed for at least 30 days.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Target Lesion Revascularization (TLR)</title>
        <description>Number of subjects experiencing a target lesion revascularization (TLR) within 9 months - Component of primary outcome</description>
        <time_frame>9 Months</time_frame>
        <population>Population includes subjects followed for at least 240 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Target Lesion Revascularization (TLR)</title>
          <description>Number of subjects experiencing a target lesion revascularization (TLR) within 9 months - Component of primary outcome</description>
          <population>Population includes subjects followed for at least 240 days.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Major Amputation</title>
        <description>Number of subjects experiencing a major amputation of the target limb within 9 months - Component of primary outcome</description>
        <time_frame>9 Months</time_frame>
        <population>Population includes subjects followed for at least 240 days.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Amputation</title>
          <description>Number of subjects experiencing a major amputation of the target limb within 9 months - Component of primary outcome</description>
          <population>Population includes subjects followed for at least 240 days.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Pain/Discomfort</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Pain/Discomfort) from pre-procedure at 36 months.</description>
        <time_frame>36 Months</time_frame>
        <population>Population includes subjects available at 36 months with relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Pain/Discomfort</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Pain/Discomfort) from pre-procedure at 36 months.</description>
          <population>Population includes subjects available at 36 months with relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Anxiety/Depression</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Anxiety/Depression) from pre-procedure at 12 months.</description>
        <time_frame>12 Months</time_frame>
        <population>Population includes subjects available at 12 months with relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Anxiety/Depression</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Anxiety/Depression) from pre-procedure at 12 months.</description>
          <population>Population includes subjects available at 12 months with relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Anxiety/Depression</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Anxiety/Depression) from pre-procedure at 24 months.</description>
        <time_frame>24 Months</time_frame>
        <population>Population includes subjects available at 24 months with relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Anxiety/Depression</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Anxiety/Depression) from pre-procedure at 24 months.</description>
          <population>Population includes subjects available at 24 months with relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Anxiety/Depression</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Anxiety/Depression) from pre-procedure at 36 months.</description>
        <time_frame>36 Months</time_frame>
        <population>Population includes subjects available at 36 months with relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Anxiety/Depression</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Anxiety/Depression) from pre-procedure at 36 months.</description>
          <population>Population includes subjects available at 36 months with relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Own Health State</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Own Health State) from pre-procedure at 12 months.</description>
        <time_frame>12 Months</time_frame>
        <population>Population includes subjects available at 12 months with relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Own Health State</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Own Health State) from pre-procedure at 12 months.</description>
          <population>Population includes subjects available at 12 months with relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Own Health State</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Own Health State) from pre-procedure at 24 months.</description>
        <time_frame>24 Months</time_frame>
        <population>Population includes subjects available at 24 months with relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Own Health State</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Own Health State) from pre-procedure at 24 months.</description>
          <population>Population includes subjects available at 24 months with relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Change in Functional Status - EQ5D - Own Health State</title>
        <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Own Health State) from pre-procedure at 36 months.</description>
        <time_frame>36 Months</time_frame>
        <population>Population includes subjects available at 36 months with relevant data.</population>
        <group_list>
          <group group_id="O1">
            <title>Iliac Stenting</title>
            <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Change in Functional Status - EQ5D - Own Health State</title>
          <description>Patient reported outcome based on study questionnaire. Number of participants with change in functional status (EQ5D - Own Health State) from pre-procedure at 36 months.</description>
          <population>Population includes subjects available at 36 months with relevant data.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Improved</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Maintained</title>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Worsened</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Iliac Stenting</title>
          <description>Balloon expandable stenting of iliac occlusive disease
Stenting of the Common and/or External Iliac Arteries: Balloon expandable stenting of iliac occlusive disease.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhagic anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Congestive cardiac failure aggravated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Rectal bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain (non-cardiac)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Vascular stent occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Surgical wound infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arterial restenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Dislocation of ankle</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Postoperative hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Postoperative ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer of prostate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Vascular dementia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COPD exacerbation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Claudication</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Femoral artery dissection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Groin hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Hypovolemic shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Leg ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Lymphocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease aggravated</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Poor peripheral perfusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
              <event>
                <sub_title>Superficial femoral arterial stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="134"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hector R Novoa</name_or_title>
      <organization>W.L. Gore &amp; Associates</organization>
      <phone>928-864-3867</phone>
      <email>hnovoa@wlgore.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

